ADC Synthesis in Flow
About the Speaker
Graham B. Jones is Professor and Chair of Chemistry & Chemical Biology at Northeastern University in Boston, MA. He also serves as director of translational research for the Tufts Medical Center Clinical and Translational Science Institute. Jones was educated in the UK, receiving BSc (1986) and PhD (1989) degrees in chemistry from the University of Liverpool and the Imperial College of Science Technology and Medicine respectively. He then moved to Harvard University as a NATO fellow to work with E. J. Corey, the 1990 Nobelist. His research program is focused on the development of experimental therapeutics and has resulted in over 140 publications and generated in excess of $30M external funding. Examples include development of antibody-toxin conjugates, treatments for polyglutamine disorders, tissue activated image contrast agents, and cancer immunotherapies. He has been appointed to several editorial posts for scientific journals and is the recipient of numerous awards including the Leblanc Medal, the Leverhulme Prize, the CEM Technology Innovation Award and a DSc degree. Jones gave invited testimony at the 2010 congressional hearings on biopharmaceuticals, and serves as scientific advisor to a number of research foundations and corporations in the USA and UK.
AbstractThe use of continuous flow technology for the synthesis of protein bioconjugates will be presented. In addition to reagent proteins, monoclonal antibody conjugates will also be highlighted.
Graham B. Jones is Professor and Chair of Chemistry & Chemical Biology at Northeastern University in Boston, MA. He also serves as director of translational research for the Tufts Medical Center Clinical and Translational Science Institute. Jones was educated in the UK, receiving BSc (1986) and PhD (1989) degrees in chemistry from the University of Liverpool and the Imperial College of Science Technology and Medicine respectively. He then moved to Harvard University as a NATO fellow to work with E. J. Corey, the 1990 Nobelist. His research program is focused on the development of experimental therapeutics and has resulted in over 140 publications and generated in excess of $30M external funding. Examples include development of antibody-toxin conjugates, treatments for polyglutamine disorders, tissue activated image contrast agents, and cancer immunotherapies. He has been appointed to several editorial posts for scientific journals and is the recipient of numerous awards including the Leblanc Medal, the Leverhulme Prize, the CEM Technology Innovation Award and a DSc degree. Jones gave invited testimony at the 2010 congressional hearings on biopharmaceuticals, and serves as scientific advisor to a number of research foundations and corporations in the USA and UK.
AbstractThe use of continuous flow technology for the synthesis of protein bioconjugates will be presented. In addition to reagent proteins, monoclonal antibody conjugates will also be highlighted.
Brought to you by
